Medina-Vicent NA, Guevara-Sanginés EG, Ramos-Rodríguez G, Juárez-Durán E, Gutiérrez-Ávila S, Arenas R

Language: Spanish
References: 30
Page: 129-138
PDF size: 336.39 Kb.

ABSTRACT

Morphea, also known as localized scleroderma, is a rare autoimmune condition characterized by inflammation and sclerosis of the skin and subcutaneous tissue. It follows a course of active phases with inflammation and fibrosis, leading to permanent tissue damage and discoloration. Uncontrolled disease activity can result in significant and irreversible cosmetic and functional sequelae, including hair loss, skin, soft tissue, and bone atrophy, joint contractures, and growth restriction in affected areas in children. Therefore, early identification of disease activity and prompt initiation of appropriate treatment are critical to minimize damage. The primary treatments for active morphea are corticosteroids and methotrexate. The limited availability of novel therapies for morphea stems from a lack of research specifically examining its pathogenesis, with many reviews relying on extrapolated data from systemic sclerosis studies.

REFERENCES

1. Papara C, De Luca DA, Bieber K, Vorobyev A y Ludwig RJ,Morphea: the 2023 update, Front Med (Lausana) 2023;13(10):1108623. doi: 10.3389/fmed.2023.1108623.

2. Wenzel D, Haddadi NS, Afshari K, Richmond JM y Rashighi M,Upcoming treatments for morphea, Immun Inflamm Dis 2021;9(4):1101-45. doi: 10.1002/iid3.475.

3. Rodríguez-Salgado P y García-Romero MT, Morphea: a practicalreview of its diagnosis, classification and treatment, Gac MedMex 2019; 155(5):483-91. doi: 10.24875/GMM.M20000336.

4. Vásquez R, Sendejo C y Jacobe H, Morphea and other localizedforms of scleroderma, Curr Opin Rheumatol 2012; 24(6):685-93.doi: 10.1097/BOR.0b013e32835896ce.

5. Fett N y Werth VP, Update on morphea: part I. Epidemiology,clinical presentation, and pathogenesis, J Am Acad Dermatol2011; 64(2):217-28; Quiz 229-30. doi: 10.1016/j.jaad.2010.05.045.

6. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, BergstresserPR y Jacobe HT, Distinct autoimmune syndromes inmorphea: a review of 245 adult and pediatric cases, Arch Dermatol2009; 145(5):545-50. doi:10.1001/archdermatol.2009.79.

7. Prasad S, Zhu JL, Schollaert-Fitch K, Torok KS y Jacobe HT, Anevaluation of the performance of current morphea subtype classifications,jama Dermatol 2021; 157(4):399-405. doi: 10.1001/jamadermatol.2020.5809.

8. Heymann WR. Morphing concepts of morphea. J Am Acad Dermatol.2021;85(1):36-37. doi: 10.1016/j.jaad.2021.04.084.

9. Florez-Pollack S, Kunzler E y Jacobe HT, Morphea: current concepts,Clin Dermatol 2018; 36(4):475-86. doi: 10.1016/j.clindermatol.2018.04.005.

10. Gavira CM, Jiménez SB y Gutiérrez G, Morfea o esclerodermialocalizada, Rev Asoc Colomb Dermatol 2014; 22(2):126-40.

11. Kurzinski K y Torok KS, Cytokine profiles in localized sclerodermaand relationship to clinical features, Cytokine 2011; 55(2):157-64. doi: 10.1016/j.cyto.2011.04.001.

12. Snarskaya ES y Vasileva KD, Localized scleroderma: actual insightsand new biomarkers, Int J Dermatol 2022; 61(6):667-74.doi: 10.1111/ijd.15811.

13. O’Brien JC, Rainwater YB, Malviya N, Cyrus N, Auer-HackenbergL, Hynan LS, Hosler GA y Jacobe HT, Transcriptional andcytokine profiles identify cxcl9 as a biomarker of disease activityin morphea, J Invest Dermatol 2017; 137(8):1663-70. doi:10.1016/j.jid.2017.04.008.

14. Abbas L, Joseph A, Kunzler E y Jacobe HT, Morphea: progressto date and the road ahead, Ann Transl Med 2021; 9(5):437. doi:10.21037/atm-20-6222.

15. Bielsa Marsol I, Actualización en la clasificación y el tratamientode la esclerodermia localizada, Actas Dermosifiliogr 2013;104(8):654-66. Disponible en: https://www.actasdermo.org/espdf-S0001731012004772.

16. Szcze‚ch J, Samotij D, Jaworecka K, Tobiasz A y Reich A, Qualityof life in patients with morphea: a cross-sectional studyand a review of the current literature, Biomed Res Int 2020;13(2020):9186274. doi: 10.1155/2020/9186274.

17. Yamamoto N, Dejima A y Hasatani K, Linear morphea involvingthe underlying muscle, Clin Rheumatol 2021; 40(11):4767-8.doi: 10.1007/s10067-021-05789-2.

18. Arif T, Fatima R y Sami M, Parry-Romberg syndrome: a minireview, Acta Dermatovenerol Alp Pannonica Adriat 2020;29(4):193-9.

19. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F y AtzoriL, Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review, Clin Rev AllergyImmunol 2017; 53(3):306-36. doi: 10.1007/s12016-017-8625-4.

20. Szczepanik-Kułak P, Michalak-Stoma A y Krasowska D, Usefulnessof dermoscopy in localized scleroderma (los, morphea)diagnosis and assessment-monocentric cross-sectional study, JClin Med 2022; 30;11(3):764. doi: 10.3390/jcm11030764.

21. Bhat YJ, Akhtar S y Hassan I, Dermoscopy of morphea, IndianDermatol Online J 2019; 10(1):92-93. doi: 10.4103/idoj.IDOJ_Ç350_17.

22. Toader MP, Pa˘tras‚cu V, Mogos‚ D, Niculescu M y Ionescu R,Dermoscopic features of localized scleroderma, Exp Ther Med2021; 21(6):584.

23. Saceda-Corralo D, Rodrígues-Barata R, Moreno-Arrones OM,Fernández-Crehuet P, Jiménez-Cauhé J, Suárez-Valle A et al.,Trichoscopic findings in en coup de sabre morphea, Australas JDermatol 2020; 61(2):e254-6.

24. Condie D, Grabell D y Jacobe H, Comparison of outcomes inadults with pediatric-onset morphea and those with adult-onsetmorphea: a cross-sectional study from the morphea in adultsand children cohort, Arthritis Rheumatol 2014; 66(12):3496-504.doi: 10.1002/art.38853.

25. Fett NM, Morphea: evidence-based recommendations for treatment,Indian J Dermatol Venereol Leprol 2012; 78(2):135-41.doi: 10.4103/0378-6323.93628.

26. Gaviria CM, Jiménez SB y Gutiérrez J. Morfea o esclerodermialocalizada, Revista de la Asociación Colombiana de Dermatologíay Cirugía Dermatológica 20214; 22(2):126-40.

27. Nezafati KA, Cayce RL, Susa JS, Setiawan AT, Tirkes T, BendeckSE y Jacobe HT, 14-MHz ultrasonography as an outcome measurein morphea (localized scleroderma), Arch Dermatol 2011;147(9):1112-5. doi: 10.1001/archdermatol.2011.243.

28. Chiu YE, Abban CY, Konicke K, Segura A y Sokumbi O, Histopathologicspectrum of morphea, Am J Dermatopathol 2021;43(1):1-8. doi: 10.1097/DAD.0000000000001662.

29. Zwischenberger BA y Jacobe HT, A systematic review of morpheatreatments and therapeutic algorithm, J Am Acad Dermatol2011; 65(5):925-41. doi: 10.1016/j.jaad.2010.09.006.

30. Walters R, Pulitzer M y Kamino H, Elastic fiber pattern inscleroderma/morphea, J Cutan Pathol 2009; 36(9):952-957.doi:10.1111/j.1600-0560.2009.01201.x.